DMARD use in RA is associated with higher rates of serious infections, tuberculosis reactivation, opportunistic infections, and possibly malignancies. Specific biologic DMARDs and higher doses are associated with elevated risks of various adverse events (gastrointestinal perforations, thromboembolism, serious infection). Shared decision-making is paramount when choosing a treatment regimen for patients based on their own comorbidities. JAKi are the newest class of medications used for RA with robust safety data provided in clinical trials. However, more real-world evidence and phase-IV pharmacovigilance data are needed to better understand comparative safety profile of DMARDs in RA.
Keyphrases
- rheumatoid arthritis
- disease activity
- clinical trial
- end stage renal disease
- ankylosing spondylitis
- rheumatoid arthritis patients
- interstitial lung disease
- newly diagnosed
- chronic kidney disease
- big data
- prognostic factors
- combination therapy
- systemic lupus erythematosus
- randomized controlled trial
- adverse drug
- risk assessment
- study protocol
- replacement therapy
- open label
- patient reported